Moderna stock has turned a handful of patient shareholders into believers, but a gain this size forces a choice that most investors never plan for in advance. The pipeline promise is real,…
A plague headline out of Siberia lifted vaccine stocks, and the agencies closest to the case have since described the risk as low. That reversal in sentiment lands hardest on Novavax (NASDAQ:NVAX),…
Sanofi just handed Novavax a commercial lifeline for the fall vaccination season, and the stock is reacting in a way that leaves Moderna and BioNTech looking like bystanders. The real question is…
Shares of Moderna (NASDAQ:MRNA | MRNA Price Prediction) are trading as though the company’s messenger RNA (mRNA) cancer vaccine has already cleared its final test, even though the complete Phase 3 dataset…
Buyers are stepping into Moderna (NASDAQ:MRNA | MRNA Price Prediction) shares, evidently. The move comes one session after a Citigroup (NYSE:C) downgrade to Sell, a sign the market still prizes the company’s…
A 100% tariff on imported drugs just expanded to cover every drugmaker in the country, yet the biotech market's most closely watched fund treated it like a non-event. The reason says everything…
Moderna (NASDAQ:MRNA | MRNA Price Prediction) stock is drawing attention Wednesday after Citigroup downgraded the biotech company to Sell from Hold, arguing that the recent rally has pushed the valuation well ahead…
A rare-disease pipeline update and a thin post-split float are combining to send Jaguar Health (NASDAQ:JAGX) sharply higher. Jaguar Health stock is up 32% to $9.32 in morning trading, a surge rooted…
Two biotech names are moving sharply lower Thursday morning while the sector benchmark grinds higher, a split move that puts the day’s action on the companies themselves rather than on any broader…
Two biotechnology names are lower in Wednesday morning trading for unrelated reasons, and the biotechnology sector itself isn’t selling off. Jaguar Health (NASDAQ:JAGX) stock is at $14.21, down 59%, while Viking Therapeutics…
Shares of Moderna (NASDAQ:MRNA | MRNA Price Prediction) are rallying again as investors position ahead of a late-October data drop that could validate the first personalized cancer therapy tested at scale. Moderna…
Moderna (NASDAQ:MRNA | MRNA Price Prediction) shares are surging Monday morning after the company announced that its Phase 3 adjuvant melanoma study for intismeran autogene, an investigational messenger RNA individualized neoantigen therapy,…
Cancer vaccine momentum is doing the work for Moderna (NASDAQ:MRNA | MRNA Price Prediction) once again on Thursday, extending one of the sharpest one-month runs in large-cap biotech this year without a…
Biotech just staged one of its sharpest reversals in years, and whether you caught it or completely missed it, the same uncomfortable question now sits in front of every portfolio: does the…
GSK just handed Moderna's biggest rival program a late-stage green light, yet traders are sending MRNA stock sharply higher. The logic behind that reaction tells you something important about where the real…
